FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387343211> ?p ?o ?g. }

• W4387343211 abstract "Objective The approval of immunotherapy (I-O) for the treatment of late-stage non-small cell lung cancer (NSCLC) opened new perspectives in improving survival outcomes. However, survival data have not yet been provided from the period of the Covid-19 pandemic. The aims of our study were to assess and compare survival outcomes of patients with advanced LC receiving systemic anticancer treatment (SACT) before and after the approval of immunotherapy in Hungary, and to examine the impact of pandemic on survival outcomes using data from the Hungarian National Health Insurance Fund (NHIF) database. Methods This retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with advanced stage lung cancer (LC) (ICD-10 C34) between 1 January 2011 and 31 December 2021 and received SACT treatment without LC-related surgery. Survival rates were evaluated by year of diagnosis, sex, age, and LC histology. Results In total, 35,416 patients were newly diagnosed with advanced LC and received SACT during the study period (mean age at diagnosis: 62.1–66.3 years). In patients with non-squamous cell carcinoma, 3-year survival was significantly higher among those diagnosed in 2019 vs. 2011–2012 (28.7% [95% CI: 26.4%–30.9%] vs. 14.45% [95% CI: 13.21%–15.69%], respectively). In patients with squamous cell carcinoma, 3-year survival rates were 22.3% (95% CI: 19.4%–25.2%) and 13.37% (95% CI: 11.8%–15.0%) in 2019 and 2011–2012, respectively, the change was statistically significant. Compared to 2011–2012, the hazard ratio of survival change for non-squamous cell carcinoma patients was 0.91, 0.82, and 0.62 in 2015–2016, 2017–2018, and 2019, respectively (p&lt;0.001 for all cases). In the squamous cell carcinoma group, corresponding hazard ratios were 0.93, 0.87, and 0.78, respectively (p&lt;0.001 for all cases). Survival improvements remained significant in both patient populations during the Covid-19 pandemic (2020–2021). No significant improvements were found in the survival of patients with small cell carcinoma. Platinum-based chemotherapy was the most common first-line treatment in all diagnostic periods, however, the proportion of patients receiving first- or second-line immunotherapy significantly increased during the study period. Conclusion 3-year survival rates of NSCLC almost doubled among patients with non-squamous cell carcinoma and significantly improved at squamous cell carcinoma over the past decade in Hungary. Improvements could potentially be attributable by the introduction of immunotherapy and were not offset by the Covid-19 pandemic." @default.
• W4387343211 created "2023-10-05" @default.
• W4387343211 creator A5002736919 @default.
• W4387343211 creator A5008333114 @default.
• W4387343211 creator A5018056024 @default.
• W4387343211 creator A5023204207 @default.
• W4387343211 creator A5032837643 @default.
• W4387343211 creator A5036647062 @default.
• W4387343211 creator A5042856214 @default.
• W4387343211 creator A5043874137 @default.
• W4387343211 creator A5047016870 @default.
• W4387343211 creator A5048348589 @default.
• W4387343211 creator A5049326416 @default.
• W4387343211 creator A5051626236 @default.
• W4387343211 creator A5067608293 @default.
• W4387343211 creator A5069675443 @default.
• W4387343211 creator A5072872385 @default.
• W4387343211 creator A5075333152 @default.
• W4387343211 creator A5078556100 @default.
• W4387343211 creator A5082305389 @default.
• W4387343211 creator A5084406752 @default.
• W4387343211 creator A5085759438 @default.
• W4387343211 creator A5086442059 @default.
• W4387343211 creator A5089319211 @default.
• W4387343211 creator A5089954353 @default.
• W4387343211 date "2023-10-04" @default.
• W4387343211 modified "2023-10-06" @default.
• W4387343211 title "Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic" @default.
• W4387343211 cites W2009955007 @default.
• W4387343211 cites W2151799520 @default.
• W4387343211 cites W2158734599 @default.
• W4387343211 cites W2163798887 @default.
• W4387343211 cites W2280957887 @default.
• W4387343211 cites W2567564314 @default.
• W4387343211 cites W2885738414 @default.
• W4387343211 cites W2921770918 @default.
• W4387343211 cites W2946386783 @default.
• W4387343211 cites W2970308923 @default.
• W4387343211 cites W2982043494 @default.
• W4387343211 cites W3006355661 @default.
• W4387343211 cites W3007415354 @default.
• W4387343211 cites W3031676068 @default.
• W4387343211 cites W3042226836 @default.
• W4387343211 cites W3083931508 @default.
• W4387343211 cites W3085632552 @default.
• W4387343211 cites W3093421366 @default.
• W4387343211 cites W3094444038 @default.
• W4387343211 cites W3103253997 @default.
• W4387343211 cites W3106631792 @default.
• W4387343211 cites W3120933346 @default.
• W4387343211 cites W3136056414 @default.
• W4387343211 cites W3137208756 @default.
• W4387343211 cites W3137314026 @default.
• W4387343211 cites W3153504580 @default.
• W4387343211 cites W3154805493 @default.
• W4387343211 cites W3159357601 @default.
• W4387343211 cites W3165293110 @default.
• W4387343211 cites W3166053636 @default.
• W4387343211 cites W3184664367 @default.
• W4387343211 cites W3201152054 @default.
• W4387343211 cites W3202925640 @default.
• W4387343211 cites W4220990951 @default.
• W4387343211 cites W4307585126 @default.
• W4387343211 cites W4309739338 @default.
• W4387343211 cites W4312054641 @default.
• W4387343211 cites W4321436832 @default.
• W4387343211 doi "https://doi.org/10.3389/fonc.2023.1207295" @default.
• W4387343211 hasPublicationYear "2023" @default.
• W4387343211 type Work @default.
• W4387343211 citedByCount "0" @default.
• W4387343211 crossrefType "journal-article" @default.
• W4387343211 hasAuthorship W4387343211A5002736919 @default.
• W4387343211 hasAuthorship W4387343211A5008333114 @default.
• W4387343211 hasAuthorship W4387343211A5018056024 @default.
• W4387343211 hasAuthorship W4387343211A5023204207 @default.
• W4387343211 hasAuthorship W4387343211A5032837643 @default.
• W4387343211 hasAuthorship W4387343211A5036647062 @default.
• W4387343211 hasAuthorship W4387343211A5042856214 @default.
• W4387343211 hasAuthorship W4387343211A5043874137 @default.
• W4387343211 hasAuthorship W4387343211A5047016870 @default.
• W4387343211 hasAuthorship W4387343211A5048348589 @default.
• W4387343211 hasAuthorship W4387343211A5049326416 @default.
• W4387343211 hasAuthorship W4387343211A5051626236 @default.
• W4387343211 hasAuthorship W4387343211A5067608293 @default.
• W4387343211 hasAuthorship W4387343211A5069675443 @default.
• W4387343211 hasAuthorship W4387343211A5072872385 @default.
• W4387343211 hasAuthorship W4387343211A5075333152 @default.
• W4387343211 hasAuthorship W4387343211A5078556100 @default.
• W4387343211 hasAuthorship W4387343211A5082305389 @default.
• W4387343211 hasAuthorship W4387343211A5084406752 @default.
• W4387343211 hasAuthorship W4387343211A5085759438 @default.
• W4387343211 hasAuthorship W4387343211A5086442059 @default.
• W4387343211 hasAuthorship W4387343211A5089319211 @default.
• W4387343211 hasAuthorship W4387343211A5089954353 @default.
• W4387343211 hasBestOaLocation W43873432111 @default.
• W4387343211 hasConcept C121608353 @default.
• W4387343211 hasConcept C126322002 @default.
• W4387343211 hasConcept C143998085 @default.
• W4387343211 hasConcept C146357865 @default.
• W4387343211 hasConcept C151730666 @default.

• next